MPLT · Insider Trading
MapLight Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by MPLT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-16 | Kristopher Hanson | General Counsel | Sell | −9,020 | −$72.88K |
| 2026-10-16 | Erin Pennock Foff | Chief Medical Officer | Sell | −15,355 | −$124.07K |
| 2026-10-16 | Anatol Kreitzer | Chief Discovery Officer | Sell | −12,248 | −$96.02K |
| 2026-10-16 | Jonathan Gillis | CAO and Interim CFO | Sell | −10,167 | −$82.15K |
| 2026-10-16 | Christopher A. Kroeger | Chief Executive Officer | Sell | −73,691 | −$595.42K |
| 2026-10-16 | James Woodruff Lillie | Chief Scientific Officer | Sell | −11,513 | −$93.03K |
| 2026-09-18 | Kristopher Hanson | General Counsel | Sell | −16,509 | −$192.66K |
| 2026-08-19 | James Woodruff Lillie | Chief Scientific Officer | A | +7,730 | — |
| 2026-08-19 | Kristopher Hanson | General Counsel | A | +7,730 | — |
| 2026-08-19 | Erin Pennock Foff | Chief Medical Officer | A | +13,360 | — |
| 2026-08-19 | Anatol Kreitzer | Chief Discovery Officer | A | +6,020 | — |
| 2026-08-19 | Christopher A. Kroeger | Chief Executive Officer | A | +23,145 | — |
| 2026-08-19 | Jonathan Gillis | CAO and Interim CFO | A | +8,242 | — |
| 2026-08-18 | Catalyst4, Inc. | 10%+ Owner | Buy | +4,400,000 | +$50.07M |
| 2026-08-04 | James Woodruff Lillie | Chief Scientific Officer | Sell | −22,082 | −$276.91K |
| 2026-07-30 | Catalyst4, Inc. | 10%+ Owner | Buy | +1,209,225 | +$15.31M |
| 2026-07-28 | Troy Cox | Director | Buy | +15,620 | +$148.70K |
| 2026-07-20 | Anatol Kreitzer | Chief Discovery Officer | Sell | −36,284 | −$1.35M |
| 2026-07-20 | Jonathan Gillis | CAO and Interim CFO | Sell | −36,979 | −$1.37M |
| 2026-07-17 | Kristopher Hanson | General Counsel | Sell | −16,508 | −$607.87K |
| 2026-07-17 | James Woodruff Lillie | Chief Scientific Officer | Sell | −18,267 | −$673.64K |
| 2026-07-17 | Erin Pennock Foff | Chief Medical Officer | Sell | −47,158 | −$1.73M |
| 2026-07-17 | Christopher A. Kroeger | Chief Executive Officer | Sell | −147,639 | −$5.44M |
| 2026-06-25 | Maria C Walker | Director | A | +3,932 | — |
| 2026-06-25 | George Pavlov | Director | A | +3,932 | — |
| 2026-06-25 | Martin Babler | Director | A | +7,864 | — |
| 2026-06-25 | Timothy John Garnett | Director | A | +3,932 | — |
| 2026-06-25 | Troy Cox | Director | A | +7,864 | — |
| 2026-06-25 | Nanna Liebach Luneborg | Director | A | +3,932 | — |
| 2026-05-18 | Christopher A. Kroeger | Chief Executive Officer | Sell | −118,235 | −$3.21M |
| 2026-05-11 | Erin Pennock Foff | Chief Medical Officer | Sell | −4,438 | −$126.64K |
| 2026-05-11 | James Woodruff Lillie | Chief Scientific Officer | Sell | −721 | −$20.39K |
| 2026-05-11 | Christopher A. Kroeger | Chief Executive Officer | Sell | −68,491 | −$1.95M |
| 2026-05-11 | Kristopher Hanson | General Counsel | Sell | −13,917 | −$419.26K |
| 2026-05-06 | James Woodruff Lillie | Chief Scientific Officer | Sell | −51,707 | −$1.47M |
| 2026-05-06 | Christopher A. Kroeger | Chief Executive Officer | Sell | −49,744 | −$1.41M |
| 2026-05-06 | Kristopher Hanson | General Counsel | Sell | −13,917 | −$388.18K |
| 2026-05-06 | Vishwas Setia | Chief Financial Officer | Sell | −36,371 | −$1.02M |
| 2026-05-06 | Erin Pennock Foff | Chief Medical Officer | Sell | −50,280 | −$1.43M |
| 2026-04-29 | Anatol Kreitzer | Chief Discovery Officer | Sell | −45,422 | −$1.35M |
| 2026-04-29 | Jonathan Gillis | CAAO and PAO | Sell | −69,835 | −$2.09M |
| 2026-04-17 | Jonathan Gillis | CAAO and PAO | Sell | −3,590 | −$95.53K |
| 2026-04-17 | Anatol Kreitzer | Chief Discovery Officer | Sell | −3,316 | −$88.24K |
| 2026-04-17 | Robert C. Malenka | Director | Sell | −8,593 | −$231.15K |
| 2026-04-17 | Christopher A. Kroeger | Chief Executive Officer | Sell | −19,187 | −$521.15K |
| 2026-04-17 | Erin Pennock Foff | Chief Medical Officer | Sell | −3,213 | −$86.86K |
| 2026-04-17 | James Woodruff Lillie | Chief Scientific Officer | Sell | −4,513 | −$122.57K |
| 2026-04-17 | Vishwas Setia | Chief Financial Officer | Sell | −2,922 | −$78.57K |
| 2026-04-17 | Kristopher Hanson | General Counsel | Sell | −1,827 | −$49.13K |
| 2026-02-24 | Robert C. Malenka | Director | Sell | −14,195 | −$260.40K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Catalyst4, Inc. | 10%+ Owner | 25,306,689 | $193.85M |
| Novo Holdings A/S | 10%+ Owner | 2,733,681 | $20.94M |
| Christopher A. Kroeger | Chief Executive Officer | 1,297,099 | $9.94M |
| Vishwas Setia | Chief Financial Officer | 378,510 | $2.90M |
| Robert C. Malenka | Director | 348,138 | $2.67M |
| Erin Pennock Foff | Chief Medical Officer | 296,906 | $2.27M |
| James Woodruff Lillie | Chief Scientific Officer | 198,597 | $1.52M |
| Anatol Kreitzer | Chief Discovery Officer | 168,678 | $1.29M |
| Jonathan Gillis | CAO and Interim CFO | 142,315 | $1.09M |
| Kristopher Hanson | General Counsel | 128,024 | $980.66K |
| Timothy John Garnett | Director | 67,581 | $517.67K |
| Maria C Walker | Director | 62,703 | $480.30K |
| George Pavlov | Director | 28,932 | $221.62K |
| Troy Cox | Director | 23,484 | $179.89K |
| Martin Babler | Director | 7,864 | $60.24K |
| Nanna Liebach Luneborg | Director | 3,932 | $30.12K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MPLT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.